Sagimet Biosciences Inc
SGMT8.655USD
+0.405+4.91%
Market hours （ET）Quotes delayed by 15 min
USD0.000Pre-market (ET)
278.65MMarket Cap
LossP/E TTM
Sagimet Biosciences Inc
8.655
+0.405+4.91%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2021Q4
FY2021Q1
Total equity
Cash, cash equivalents and short-term investments
-25.37%144.57M
59.38%151.25M
49.73%152.49M
798.92%166.37M
667.03%193.71M
--94.90M
--101.84M
--18.51M
--25.25M
--56.73M
--74.94M
- Cash and cash equivalents
-63.39%64.72M
0.93%75.84M
-24.38%77.01M
418.47%95.96M
1332.78%176.78M
--75.14M
--101.84M
--18.51M
--12.34M
--56.73M
--74.94M
-Short-term investments
371.72%79.85M
281.67%75.41M
--75.47M
--70.41M
31.06%16.93M
--19.76M
--0.00
--0.00
--12.92M
----
----
Prepaid expenses
-9.29%615.00K
-21.52%1.06M
379.04%4.30M
143.14%248.00K
79.37%678.00K
--1.35M
--897.00K
--102.00K
--378.00K
--423.00K
--1.10M
Other current assets
722.22%888.00K
16.62%463.00K
428.57%407.00K
-95.26%130.00K
-92.37%108.00K
--397.00K
--77.00K
--2.74M
--1.42M
--1.51M
--963.00K
Total current assets
-24.90%146.07M
58.08%152.77M
52.88%157.19M
680.89%166.75M
619.06%194.49M
--96.65M
--102.82M
--21.35M
--27.05M
--58.66M
--77.01M
Non-current assets
Net Fixed Assets
2.70%38.00K
5.48%77.00K
4.59%114.00K
4.86%151.00K
-79.21%37.00K
--73.00K
--109.00K
--144.00K
--178.00K
--342.00K
--161.00K
Other non-current assets
--62.00K
----
----
----
----
----
----
----
----
----
----
Total non-current assets
170.27%100.00K
10153.42%7.49M
16033.03%17.59M
15364.58%22.27M
-81.95%37.00K
--73.00K
--109.00K
--144.00K
--205.00K
--369.00K
--188.00K
Total assets
-24.86%146.17M
65.70%160.26M
69.81%174.78M
779.24%189.02M
613.79%194.53M
--96.72M
--102.92M
--21.50M
--27.25M
--59.03M
--77.20M
Liabilities
Current liabilities
-Other payables
--16.00K
-97.85%5.00K
-88.42%11.00K
-90.29%10.00K
-100.00%0.00
--233.00K
--95.00K
--103.00K
--167.00K
--185.00K
--349.00K
Accrued expenses
-1.29%3.90M
-43.02%2.95M
-10.67%2.81M
53.86%3.57M
12.24%3.95M
--5.17M
--3.15M
--2.32M
--3.52M
--1.37M
--767.00K
Short-term debt and lease liabilities
----
----
----
----
----
----
--0.00
--0.00
--0.00
--0.00
--0.00
Other current liabilities
--16.00K
-97.85%5.00K
-88.42%11.00K
-90.29%10.00K
-100.00%0.00
--233.00K
--95.00K
--103.00K
--167.00K
--185.00K
--349.00K
Total current liabilities
59.20%7.18M
-21.22%4.45M
-18.95%4.09M
8.34%5.73M
-14.70%4.51M
--5.65M
--5.05M
--5.29M
--5.29M
--2.44M
--3.13M
Non-current liabilities
Long-term debt and lease liabilities
--0.00
--0.00
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
--0.00
--39.00K
--224.00K
--27.00K
-Long-term debt
----
----
----
----
----
----
--0.00
--0.00
--0.00
--0.00
--0.00
-Long-term lease liabilities
----
----
----
----
----
--0.00
--0.00
--0.00
--39.00K
--224.00K
--27.00K
Other non-current liabilities
--0.00
----
----
----
----
----
---1.14K
--0.00
--0.00
--0.00
--0.00
Total non-current liabilities
----
----
----
----
----
--0.00
---1.14K
--5.00K
--45.00K
--231.00K
--36.00K
Total liabilities
59.20%7.18M
-21.22%4.45M
-18.94%4.09M
8.24%5.73M
-15.42%4.51M
--5.65M
--5.05M
--5.29M
--5.33M
--2.67M
--3.16M
Shareholders' equity
Common equity
1.34%452.36M
32.31%450.89M
32.37%449.35M
1116.01%447.81M
1147.96%446.38M
--340.78M
--339.47M
--36.83M
--35.77M
--33.11M
--31.89M
Preferred equity
----
----
----
----
----
----
----
--214.62M
--214.62M
--214.62M
--214.62M
Retained earnings
-22.28%-313.49M
-18.25%-295.31M
-15.53%-279.11M
-12.43%-264.49M
-12.22%-256.37M
---249.74M
---241.59M
---235.24M
---228.46M
---191.37M
---172.47M
Capital reserves
1.34%452.36M
32.31%450.88M
32.37%449.35M
1116.03%447.80M
1147.99%446.38M
--340.78M
--339.47M
--36.83M
--35.77M
--33.11M
--31.89M
Gains losses not affecting retained earnings
1628.57%121.00K
666.67%230.00K
--441.00K
---23.00K
153.85%7.00K
--30.00K
--0.00
--0.00
---13.00K
----
----
Total equity
-26.85%138.99M
71.09%155.81M
74.38%170.68M
1031.01%183.29M
766.83%190.02M
--91.06M
--97.88M
--16.21M
--21.92M
--56.36M
--74.04M
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
